Live from the NIH registry
Studies recruiting near Thousand Oaks right now
Top 25 of 677 recruiting studies, sorted by proximity — each links to its official registry page
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3
Interventional 540 participants sought
Beverly Hills Cancer Center — Beverly Hills, California (28.4 mi)
· Sponsor: Relay Therapeutics, Inc.
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Solid Tumor, Non-Small-Cell Lung Cancer
Phase 1
Interventional 364 participants sought
UCLA Santa Monica Hematology Oncology — Santa Monica, California (25.0 mi)
· Sponsor: Astellas Pharma Inc
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
Angiokeratomas
Phase 2
Interventional 15 participants sought
Unified Health — Sherman Oaks, California (24.5 mi)
· Sponsor: Palvella Therapeutics, Inc.
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Systemic Lupus Erythematosus
Phase 3
Interventional 550 participants sought
Millennium Clinical Trials — Westlake Village, California (5.1 mi)
· Sponsor: Novartis Pharmaceuticals
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Gout
Phase 3
Interventional 500 participants sought
Cohen Medical Centers — Thousand Oaks, California (2.6 mi)
· Sponsor: Crystalys Therapeutics
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
Uncontrolled Hypertension
Phase 2
Interventional 280 participants sought
Retension Clinical Site — West Hills, California (13.2 mi)
· Sponsor: Retension Pharmaceuticals. Inc.
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Geographic Atrophy, Macular Degeneration
N/A
Observational 500 participants sought
The Retina Partners — Encino, California (21.5 mi)
· Sponsor: Astellas Pharma Global Development, Inc.
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Atherosclerotic Cardiovascular Disease (ASCVD)
Phase 3
Interventional 340 participants sought
Interv Cardiology Med Grp — West Hills, California (13.2 mi)
· Sponsor: Novartis Pharmaceuticals
Title: A Multimodal Exercise Program With Gamification for Parkinson Disease (MEP+G)
Parkinson Disease
EARLY/Phase 1
Interventional 50 participants sought
Equilibrium Physical Therapy — Ventura, California (24.6 mi)
· Sponsor: California State University, Northridge
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
Phase 1
Interventional 1,006 participants sought
UCLA Department of Medicine - Hematology & Oncology — Santa Monica, California (25.0 mi)
· Sponsor: Seagen, a wholly owned subsidiary of Pfizer
A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individuals Utilizing GLP-1 RAs
Nutrition Intake, Nutrition Status
N/A
Interventional 120 participants sought
Citruslabs — Santa Monica, California (25.0 mi)
· Sponsor: Athletic Greens International
Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis
Knee Cartilage Defects
Phase 3
Interventional 300 participants sought
Source Healthcare — Santa Monica, California (25.0 mi)
· Sponsor: Medipost, Inc.
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
Type 2 Diabetes
Phase 2
Interventional 60 participants sought
Hope Clinical Research — Canoga Park, California (15.9 mi)
· Sponsor: Biomea Fusion Inc.
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Advanced Solid Tumors
Phase 1, Phase 2
Interventional 220 participants sought
Sarcoma Oncology Center — Santa Monica, California (25.0 mi)
· Sponsor: Pyxis Oncology, Inc
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Relapsed Refractory Multiple Myeloma
Phase 3
Interventional 508 participants sought
Research Site — Santa Monica, California (25.0 mi)
· Sponsor: AstraZeneca
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
Bacterial Conjunctivitis
Phase 3
Interventional 400 participants sought
Baxis Site 20 — Sherman Oaks, California (24.5 mi)
· Sponsor: Baxis Pharmaceuticals, Inc.
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Prostate Cancer
Phase 4
Interventional 700 participants sought
Providence Saint Johns Health Ctr — Santa Monica, California (25.0 mi)
· Sponsor: Novartis Pharmaceuticals
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis, Ulcerative Colitis Chronic
Phase 2
Interventional 140 participants sought
Clinical Trials Management Services, LLC — Thousand Oaks, California (2.6 mi)
· Sponsor: Eli Lilly and Company
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Multiple conditions
Phase 2
Interventional 150 participants sought
Tower Cancer Research Foundation — Beverly Hills, California (28.4 mi)
· Sponsor: National Cancer Institute (NCI)
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Advance Solid Tumors
Phase 1
Interventional 76 participants sought
Kivu Trial Site — Santa Monica, California (25.0 mi)
· Sponsor: Kivu Bioscience Inc.
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
Atopic Dermatitis
Phase 3
Interventional 180 participants sought
Clinical Trials Research Institute — Thousand Oaks, California (2.6 mi)
· Sponsor: Organon and Co
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Phase 3
Interventional 582 participants sought
Research Site — Santa Monica, California (25.0 mi)
· Sponsor: AstraZeneca
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
Breast Cancer, Breast Tumor
Phase 1, Phase 2
Interventional 18 participants sought
Sarcoma Oncology Center — Santa Monica, California (25.0 mi)
· Sponsor: BriaCell Therapeutics Corporation
Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved.
Phantom Limb Syndrome With Pain
Phase 2, Phase 3
Interventional 30 participants sought
Mystic Health — Santa Monica, California (25.0 mi)
· Sponsor: The Ketamine Research Foundation
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
Staphylococcus Aureus
Phase 1, Phase 2
Interventional 231 participants sought
Research Site — Oxnard, California (17.2 mi)
· Sponsor: AstraZeneca